[{"from": "human", "value": "What can you tell me about this molecule? [C][C][Branch2][Branch1][=Branch1][C][C][Branch1][Ring2][C][Ring1][Ring2][Branch2][Ring2][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][Branch2][Ring1][Ring2][N][C][O][C][=C][Branch1][#Branch1][C][Ring1][=Branch1][=N][Ring1][=Branch2][C][=N][C][=C][Ring1][Branch2][C][=C][C][=C][C][=C][Ring1][=Branch1][N][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable allosteric and selective pan-inhibitor of the serine/threonine protein kinase Akt (protein kinase B; v-akt murine thymoma viral oncogene homolog 1), with potential antineoplastic activity. Upon oral administration, Akt inhibitor TAS-117 targets, binds to and inhibits the activity of Akt, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents."}]